UCB U.S. News

UCB's Global Corporate Website

Welcome to UCB in the United States

Healthcare Professionals

Patients

Investors

10 UCB Launches Make HStory, an Educational Campaign Offering Resources and Support for Those Living with Hidradenitis Suppurativa

Read More Share:

Apr

04 FDA Accepts Supplemental Biologics License Applications for BIMZELX® (bimekizumab-bkzx) for Moderate-to-Severe Hidradenitis Suppurativa and Additional 2mL Device Presentations

Read More Share:

Mar

19 Patty Fritz and Bianca Anderson Recognized by the Healthcare Businesswomen’s Association (HBA) as UCB Luminary and Rising Star

Read More Share:

Mar

09 First Presentation of Year 4 BIMZELX® (bimekizumab-bkzx) Data Showed Long-Term Maintenance of Complete Skin Clearance in Moderate-to-Severe Plaque Psoriasis

Read More Share:

Mar

08 BIMZELX® 48-Week Phase 3 Analyses in Moderate-to-Severe Hidradenitis Suppurativa Showed Sustained Improvements in Skin Pain and Draining Tunnel Count

Read More Share:

Mar

07 Innovating and collaborating in immuno-dermatology: a dialogue with UCB’s Simon Lucas & Camille Lee

Read More Share:

Mar

06 Putting People First to Create a More Sustainable Healthcare System

Read More Share:

Feb

28 UCB on Growth Path for a Decade Plus

Read More Share:

Feb

22 Rare Disease Day 2024: The Moment is Now to Be Patient-First to Deliver for People Living with Rare Diseases

Read More Share:

Feb

12 Harmony in Health: Partnering for Enhanced Seizure Management and Understanding

Read More Share:

Categories

Archives

Apr

10

UCB Launches Make HStory, an Educational Campaign Offering Resources and Support for Those Living with Hidradenitis Suppurativa

Apr

04

FDA Accepts Supplemental Biologics License Applications for BIMZELX® (bimekizumab-bkzx) for Moderate-to-Severe Hidradenitis Suppurativa and Additional 2mL Device Presentations

Mar

19

Patty Fritz and Bianca Anderson Recognized by the Healthcare Businesswomen’s Association (HBA) as UCB Luminary and Rising Star

Mar

09

First Presentation of Year 4 BIMZELX® (bimekizumab-bkzx) Data Showed Long-Term Maintenance of Complete Skin Clearance in Moderate-to-Severe Plaque Psoriasis

Mar

08

BIMZELX® 48-Week Phase 3 Analyses in Moderate-to-Severe Hidradenitis Suppurativa Showed Sustained Improvements in Skin Pain and Draining Tunnel Count

Mar

07

Innovating and collaborating in immuno-dermatology: a dialogue with UCB’s Simon Lucas & Camille Lee

Mar

06

Putting People First to Create a More Sustainable Healthcare System

Feb

28

UCB on Growth Path for a Decade Plus

Feb

22

Rare Disease Day 2024: The Moment is Now to Be Patient-First to Deliver for People Living with Rare Diseases

Feb

12

Harmony in Health: Partnering for Enhanced Seizure Management and Understanding

Choose Country

UCB in the U.S.

Innovation

Disease Areas

Sustainability

Newsroom

Contact

Categories

Archives

Apr

10

UCB Launches Make HStory, an Educational Campaign Offering Resources and Support for Those Living with Hidradenitis Suppurativa

Apr

04

FDA Accepts Supplemental Biologics License Applications for BIMZELX® (bimekizumab-bkzx) for Moderate-to-Severe Hidradenitis Suppurativa and Additional 2mL Device Presentations

Mar

19

Patty Fritz and Bianca Anderson Recognized by the Healthcare Businesswomen’s Association (HBA) as UCB Luminary and Rising Star

Mar

09

First Presentation of Year 4 BIMZELX® (bimekizumab-bkzx) Data Showed Long-Term Maintenance of Complete Skin Clearance in Moderate-to-Severe Plaque Psoriasis

Mar

08

BIMZELX® 48-Week Phase 3 Analyses in Moderate-to-Severe Hidradenitis Suppurativa Showed Sustained Improvements in Skin Pain and Draining Tunnel Count

Mar

07

Innovating and collaborating in immuno-dermatology: a dialogue with UCB’s Simon Lucas & Camille Lee

Mar

06

Putting People First to Create a More Sustainable Healthcare System

Feb

28

UCB on Growth Path for a Decade Plus

Feb

22

Rare Disease Day 2024: The Moment is Now to Be Patient-First to Deliver for People Living with Rare Diseases

Feb

12

Harmony in Health: Partnering for Enhanced Seizure Management and Understanding

Choose Country

UCB in the U.S.

Innovation

Disease Areas

UCB Worldwide

Sustainability

Newsroom

Contact